 | | Vol. 16.00 – 4 January, 2024 |
| |
|
|
| The authors found that deficiency in tumor glycolysis activated a metabolic switch from glycolysis to fatty acid β-oxidationtion to fuel TNBC growth.
[Cell Metabolism] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers determined that a stiff matrix and high mechanosignaling increase mammary epithelial stem-progenitor cell frequency and enhance tumor initiation in vivo.
[Cell Stem Cell] |
|
|
|
| Investigators adapted the skin organoid model, inducing the dermal mesenchyme to transform into mammary-specific mesenchyme via the sequential activation of Bone Morphogenetic Protein 4 and Parathyroid Hormone-related Protein and inhibition of hedgehog signaling.
[Developmental Cell] |
|
|
|
| Aflibercept was radiolabeled with 89Zr and 177Lu via the conjugation of chelators. Flow cytometry and cell immunofluorescent staining were performed to evaluate the binding affinity of Abe.
[European Journal Of Nuclear Medicine And Molecular Imaging] |
|
|
|
| Scientists showed that lactogenic differentiation of murine mammary epithelial cells requires silencing of genes encoding ribosomal RNA (rRNA) by the antisense transcript PAPAS.
[Cell Reports] |
|
|
|
| Investigators showed that FBXO3 played a vital role in PI3K-mediated breast cancer metastasis independent of its E3 ligase activity and ΔNp63α in breast cancer cells and in mouse.
[PLOS Biology] |
|
|
|
| Researchers reported a strong downregulation of epithelial Wnt/β-catenin activity as the mammary bud progressed to branching.
[Journal Of Investigative Dermatology] |
|
|
|
| Scientists qualified a breast cancer-specific antibody panel, including HER2, ER, and PR, for multiplexed tissue imaging. They then compared the performance of these antibodies against established clinical standards using pixel-, cell- and tissue-level analyses, utilizing 866 tissue cores
[NPJ Breast Cancer] |
|
|
|
|
|
| The authors address important aspects concerned with different methods used for studying breast cancer- and g canine mammary gland tumors-related tumor microenvironment that are important for developing new and more effective therapeutic strategies for attacking a tumor during specific evolutionary stages.
[Biochimica Et Biophysica Acta-Reviews On Cancer] |
|
|
|
|
| Avenzo Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 selective inhibitor globally.
[Avenzo Therapeutics] |
|
|
|
|
| February 21 – 24, 2024
San Antonio, Texas, United States |
|
|
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | BC Cancer – Vancouver, British Columbia, Canada |
|
|
|
| | Human Technopole – Location |
|
|
|
| | University of Melbourne – Melbourne, Australia |
|
|
|
| | Zhejiang Chinese Medical University – Hangzhou, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
